Enzeevu (aflibercept-abzv) / Sandoz, Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enzeevu (aflibercept-abzv) / Sandoz
NCT05161806: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Completed
3
30
US
SOK583A1 (40 mg/mL), aflibercept, Prefilled Syringe (PFS)
Sandoz
Neovascular Age-related Macular Degeneration (nAMD)
05/22
05/22
Mylight, NCT04864834 / 2019-004838-41: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Completed
3
485
Europe, Japan, US, RoW
SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL)
Sandoz
Neovascular Age-related Macular Degeneration
07/22
05/23
NCT05282004: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Completed
3
36
US
SOK583A1
Sandoz
Neovascular Age-related Macular Degeneration (nAMD)
09/22
09/22

Download Options